Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purpose of the present study was the characterization of the receptors participating in the regulatory mechanism of glial
Na+
/K+-ATPase by serotonin (5-HT) in rat brain. The activity of the
Na+
pump was measured in four brain regions after incubation with various concentrations of serotoninergic agonists or antagonists. A concentration-dependent increase in enzyme activity was observed with the
5-HT1A
agonist R (+)-2-dipropylamino-8-hydroxy-1,2,3, 4-tetrahydronaphthalene hydrobromide (8-OH-DPAT) in homogenates or in glial membrane enriched fractions from cerebral cortex and in hippocampus. Spiperone, a
5-HT1A
antagonist, completely inhibited the response to 8-OH-DPAT but had no effect on
Na+
/K+-ATPase activity in cerebellum where LSD, a 5-HT6 agonist, elicited a dose-dependent response similar to that of 5-HT. In brainstem, a lack of response to 5-HT and other agonists was confirmed. Altogether, these results show that serotonin modulates glial
Na+
/K+-ATPase activity in the brain, apparently not through only one type of 5-HT receptor. It seems that the receptor system involved is different according to the brain region. In cerebral cortex, the response seems to be mediated by
5-HT1A
as well as in hippocampus but not in cerebellum where 5-HT6 appears as the receptor system involved.
...
PMID:Regulation of glial Na+/K+-ATPase by serotonin: identification of participating receptors. 1034 93
The study was conducted on a human (Jurkat) T cell line, loaded with a
Na+
fluorescent probe, SBFI/AM. Serotonin and an agonist of 5-HT3 receptor-channels, 2-methyl-5HT, evoked
Na+
influx, whereas the agonists of other serotonergic receptor subtypes, i.e.,
5-HT1A
and 5-HT1B receptors, failed to induce
Na+
influx in these cells. By using 3H-BRL43694, an agonist of 5-HT3 receptor-channels, we characterized 5-HT3 lymphocyte receptors which exhibited a density (Bmax) of 300 +/- 20 fmol/10(6) cells and a Kd of 30 nM in Jurkat T cells. The T-cell 5-HT3 receptor-channel is not regulated either by the protein kinase C or by the free intracellular calcium concentrations as the agents known to activate the PKC and to induce increases in intracellular free calcium concentrations failed to influence the free intracellular
Na+
concentrations, [
Na+
]i, in these cells. Furthermore, an increase in [
Na+
]i, induced by 2-methyl-5HT, via 5-HT3 receptor-channels seems to stimulate T-cell activation by facilitating the progression of T cells from S to G2/M phase of the cell cycle.
...
PMID:5-HT3 receptor-channels coupled with Na+ influx in human T cells: role in T cell activation. 1049 77
Mechanisms of agonist and inverse agonist action at the serotonin
5-HT1A
receptor have been studied using the modulation of guanosine 5'-O-(3-[35S]thiotriphosphate) ([35S]GTPgammaS) binding in membranes of Chinese hamster ovary (CHO) cells expressing the receptor (CHO-5-HTA1A cells). A range of agonists increased [35S]GTPgammaS binding with different potencies and to different maximal extents, whereas two compounds, methiothepin and spiperone, inhibited both agonist-stimulated and basal [5S]GTPgammaS binding, thus exhibiting inverse agonism. Potencies of agonists to stimulate [35S]GTPgammaS binding in membranes from CHO-
5-HT1A
cells were reduced by adding increasing concentrations of GDP to assays, whereas changes in
sodium ion
concentration did not affect agonist potency. The maximal effect of the agonists was increased by increasing
sodium ion
concentrations. The affinities of agonists in ligand binding assays were unaffected by changes in
sodium ion
concentration. Increasing GDP in the assays of the inverse agonists increased potency for spiperone to inhibit [35S]GTPgammaS binding and had no effect for methiothepin, in agreement with the sensitivity of these compounds to guanine nucleotides in ligand binding assays. Potencies for these inverse agonists were unaffected by changes in
sodium ion
concentration. These data were simulated using the extended ternary complex model. These simulations showed that the data obtained with agonists were consistent with these compounds achieving agonism by stabilising the ternary complex. For inverse agonists, the simulations showed that the mechanism for spiperone may be to stabilise forms of the receptor uncoupled from G proteins. Methiothepin, however, probably does not alter the equilibrium distribution of different receptor species; rather, this inverse agonist may stabilise an inactive form of the receptor that can still couple to G protein.
...
PMID:Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors. 1061 39
Recently we reported that rat taste receptor cells respond to the neurotransmitter serotonin with an inhibition of a calcium-activated potassium current [17]. In the present study, this observation is confirmed and extended by studying the effects of an array of serotonergic agonists on membrane properties, calcium-activated potassium current, and voltage-dependent
sodium
current in taste receptor cells using the patch-clamp recording technique in the whole-cell configuration. Serotonergic inhibition of calcium-activated potassium current was mimicked by the agonists N-(3-trifluoromethylphenyl)piperazine and by (+/-)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene. Both produced reversible inhibition of K(Ca) as well as significantly increasing the input resistance of the cell. The agonists 1-(1-naphthyl)piperazine and buspirone (both
serotonin receptor 1A
agonists) were similarly effective in reducing K(Ca). Outward current was unaffected by application of phenylbiguanide, a serotonin receptor 3 agonist, though current was affected by subsequent application of (+/-)-2-dipropylamino-8-hydroxy-1,2,3, 4-tetrahydronaphthalene. Two agonists-N-(3-trifluoromethylphenyl)piperazine and (+/-)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene-were also tested on voltage-dependent
sodium
currents; both were effective and reversible in reducing its magnitude at a variety of applied potentials. These data are consistent with the notion that serotonin effects in rat taste receptor cells are mediated by serotonin 1A receptors, though other receptor subtypes may be additionally expressed. Serotonin may affect the taste cell electrical properties during active stimulation in a paracrine fashion.
...
PMID:Serotonergic agonists inhibit calcium-activated potassium and voltage-dependent sodium currents in rat taste receptor cells. 1063 Sep 28
Dopamine D3 receptors may be involved in drug addiction and in disorders such as schizophrenia and Parkinson's disease. To determine the pharmacological properties of dopamine D3 receptors in the rat caudate-putamen, we have investigated R(+)-[3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin ([3H]R(+)-7-OH-DPAT) binding to membrane preparations from the rat caudate-putamen. Kinetic analyses showed that [3H]R(+)-7-OH-DPAT binding reached equilibrium in approximately 1 h and that both association and dissociation curves were composed of at least two components. Likewise, saturation curves showed at least two binding components with a combined Bmax value of about 600 fmol/mg protein, which is three times higher than what is present in the subcortical limbic area. Competition curves were performed with agonists such as R(-)-propylnorapomorphine, dopamine, PD 128907, quinpirole, and bromocriptine, and antagonists such as haloperidol, raclopride, clozapine, GR 218231x, remoxipride, and U99194A. These experiments revealed that [3H]R(+)-7-OH-DPAT binding could be resolved into three specific binding sites (R1-R3) and one nonspecific binding site, with R1-R2 probably representing D3 receptor binding and the minor R3 representing D2 receptor binding. The low affinities of (+/-)-8-OH-DPAT and 1,3-di(2-tolyl)guanidine to inhibit [3H]R(+)-7-OH-DPAT binding indicate negligible involvement of
5-HT1A
or sigma binding sites, respectively. The pharmacological profile of [3H]R(+)-7-OH-DPAT (2 nM) binding in the caudate-putamen was similar to that of dopamine on [125I]iodosulpride binding in the cerebellar lobule X, which contain D3 but not D2 receptors. Mg2+ increased and GTP and
Na+
decreased the binding of [3H]R(+)-7-OH-DPAT, suggesting a coupling of endogenous D3 receptors to G proteins. Taken together, these results suggest that dopamine D3 receptors display multiple agonist binding states, and that D3 receptors are present in high concentrations in the rat caudate-putamen. These results may have implications for the physiological and pathological roles of dopamine D3 receptors in the brain.
...
PMID:Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. 1091 86
Various classes of compounds exist to lower intraocular pressure (IOP) in the treatment of glaucoma. None of them is ideal since some patients respond better than others and the side effects vary between individuals. New classes of compounds need to be introduced to allow the clinician greater scope for effective treatment of all patients. It is now generally agreed that the cause of ganglion cell dysfunction in glaucoma is likely to be multifactorial and that concentrating solely on reducing IOP is inadequate. Irrespective of the reason for the dysfunction, the future goal must be to attenuate cell death. This may be achieved with drugs that interact with components of the retina, and is termed 'neuroprotection'. Thus, drugs that can both reduce IOP and act as neuroprotectants would be ideal for the treatment of glaucoma. In this article we summarise studies on animals which show serotonergic
5-HT1A
agonists to both reduce IOP when topically applied to the rabbit eye and blunt the damaging effect to the rat retina and ganglion cells induced by glutamate toxicity or ischaemia. Reduction of IOP occurs via stimulation of
5-HT1A
receptors associated with the ciliary processes. Neuroprotection of retinal neurones appears to involve the interaction of
5-HT1A
agonists with membrane
sodium
channels and/or
5-HT1A
or even possibly 5-HT7 receptors. Various
5-HT1A
agonists are used in patients to treat depression, so classes of these drugs have a proven safety profile for use in patients. The animal studies summarised in this article suggest that
5-HT1A
agonists need to be considered as a new class of drugs for the treatment of glaucoma.
...
PMID:5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies. 1102 74
Hypericum possesses a unique pharmacology in that it displays the pharmacology of many classes of antidepressants and new mechanisms not typical of standard antidepressants. The most potent of all its action is the moderate to high potency for inhibition of the reuptake of monoamines, serotonin, dopamine and noradrenaline and the amino-acid neurotransmitters GABA and glutamate. Unlike standard reuptake inhibitors, hypericum exerts this reuptake inhibition non-competitively by enhancing intracellular
Na+
ion concentrations. At a receptor level, chronic treatment with hypericum downregulates beta1-adrenoceptor, upregulates post-synaptic
5-HT1A
receptors and 5-HT2 receptors. Although the major constituent responsible for the antidepressant effect is thought to be hyperforin, other constituents such as hypericin, pseudohypericin, flavonoids and oligomeric procyanidines may also play a direct or indirect role. While reuptake inhibition may more than likely be responsible for most of the antidepressant effect, other mechanisms may also contribute alone or in combination to exert the overall antidepressant action.
...
PMID:Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. 1127 8
The intrarenal natriuretic hormone dopamine (DA) is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). We have previously shown that inhibition of COMT by entacapone results in a potent D1-like receptor-mediated natriuretic response. The present study was performed using anaesthetized rats to compare the importance of MAO and COMT in DA-mediated natriuresis by use of the MAO inhibitor phenelzine. Urinary
sodium
and DA excretion remained unchanged after MAO inhibition, while excretion of the main metabolite dihydroxyphenylacetic acid (DOPAC) decreased by 55%. The response was unaltered if 5-hydroxytryptamine receptors (
5-HT1A
) were blocked during MAO inhibition. We also investigated the specific renal activities of MAO and COMT in rat renal cortex during DA-influenced natriuresis. Specific COMT activity in the renal cortex was reduced by 13% after isotonic
sodium
loading (5% of body mass) whereas renal MAO-A and MAO-B activities remained unaltered. Furthermore, preliminary data obtained from spontaneously hypertensive rats, whose basal urinary DA excretion is higher than that of normotensive Wistar-Kyoto rats, show a tendency for renal COMT activity to be lower. It is concluded that MAOinhibition by phenelzine does not alter
sodium
excretion. Furthermore, specific renal cortical COMT activity is reduced during partly D1-like receptor-mediated natriuresis, whereas MAO activity remains unchanged. The results suggest that MAO is less important than COMT in regulating DA-mediated natriuresis in the rat kidney.
...
PMID:The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat. 1151 Aug 81
Factors influencing the disappearance of radioactivity from mouse brain after injections of tracer doses of the very selective receptor antagonists [3H]raclopride and [3H]robalzotan (NAD-299) which bind with high affinity to dopamine-D2 and 5-hydroxytryptamine1A receptors, respectively, were studied. For both ligands the amount of radioactivity in cerebellum was taken as non-specific binding and subtracted from the amount of radioactivity found in the brain regions studied. The disappearance of the radioactivity in naive mice followed apparent first-order reactions with T1/2=16.8+/-1.4 min for [3H]raclopride in striatum and T1/2=22+/-2 min and 17+/-2 min for [3H]robalzotan in hippocampus and frontal cortex, respectively. Pretreatment of mice with 1 mg/kg s.c. reserpine 20 h before the experiment strongly prolonged the dissociation phase for the two ligands. Injection of the dopamine-D2 receptor antagonist etioclopride 1 h after [3H]raclopride in the reserpinized mice rapidly reduced the radioactivity in striatum to the same level as in cerebellum. Similarly, the
5-HT1A
receptor antagonist WAY-100,635 injected 1 h or 4 h after [3H]robalzotan rapidly reduced the radioactivity in hippocampus and frontal cortex to the cerebellum level showing that the intact drugs were still bound to the receptors. In reserpinized mice kept at 30 degrees C 1 h before and during the experiment, which normalised the body temperature, the disappearance of radioactivity was more like that in untreated animals but was still significantly higher than in the control animals. Mice treated with anaesthetic agents, e.g. gamma-butyrolactone (GBL), pentobarbital
sodium
and chloral hydrate, also strongly prolonged the rate of disappearance of [3H]raclopride and [3H]robalzotan from the receptor-rich brain regions. The pronounced effect of hypothermia on the dissociation of these 3H ligands from their receptors is probably caused by a general decrease in brain nervous activity. However, the decreased rate of dissociation evoked by reserpine, GBL, baclofen and prazosin after normalisation of the body temperature may be due to specific actions of these compounds causing decrease in dopaminergic and serotoninergic nerve activity which results in reduced synaptic concentration of the transmitter amines. In accordance with this view, increased synaptic 5-HT evoked by the 5-HT releasing agent p-chloroamphetamine enhanced the disappearance of [3H]robalzotan from hippocampus and frontal cortex.
...
PMID:Hypothermia reduces the rate of dissociation of specific ligands from dopamine-D2 and 5-hydroxytryptamine1A receptors in the mouse brain in vivo. 1169 32
The effects of compounds that open the GABAA receptor-chloride channel complex on the rapidly developed tolerance to the 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide(8-OH-DPAT)-induced hypothermia in rats were examined. The test compound was injected 15 min. before 1 mg/kg subcutaneous 8-OH-DPAT or saline and 24 hr later a challenge dose of 0.1 mg/kg subcutaneous 8-OH-DPAT was given. The rectal temperature was measured before the challenge dose and 30, 60, 90 and 120 min. thereafter. The hypothermic effect was calculated as the area under the curve. It was found that all the GABAergic compounds examined significantly counteracted the 8-OH-DPAT-induced tolerance to the hypothermic response: muscimol at 3 mg/kg subcutaneous, diazepam at 1 - 3 mg/kg subcutaneous, pentobarbitone
sodium
at 20 mg/kg subcutaneous, and chlormethiazole at 40 mg/kg subcutaneous. Combined treatment of the rats with the GABAA receptor antagonist, bicucculine, or the GABAA receptor-chloride channel blocker, picrotoxin and diazepam, pentoparbitone
sodium
or chlormethiazole significantly antagonised this counteraction of the 8-OH-DPAT-induced tolerance. Depletion of 5-HT by pretreatment of the rats with the tryptophan hydroxylase inhibitor p-chlorophenylalanine did not counteract the 8-OH-DPAT-induced tolerance to the hypothermic response. Pretreatment of the rats with dexamethazone did not change the development of the tolerance to 8-OH-DPAT-induced hypothermic effect which seems to exclude the involvement of the hypothalamo-pituitary-adrenocortical axis in the tolerance development. It is concluded that the results support the hypothesis that GABA neurones beyond the 5-HT neurones are involved in the mechanism causing tolerance to the
5-HT1A
receptor-mediated hypothermia in rats.
...
PMID:Counteraction of the rapid tolerance to 8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia in rats by activation of the GABAA receptor-chloride channel complex. 1200 7
<< Previous
1
2
3
4
5
6
7
Next >>